SEC EDGARJUL 12 min read$CTNM

Stengone Carmine N. sold $160K of CTNM

Stengone Carmine N. (CEO and President) sold 10,000 shares of Contineum Therapeutics, Inc. (CTNM) at $16.01 ($0.16M total) on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Stengone Carmine N.

Published Jul 1, 2026, 11:04 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 1, 2026, 11:05 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CTNM

Neutral

medium confidence

Mentioned

$CTNM

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CTNMNeutralLow

Why it matters

The CEO’s open-market sale under a pre-arranged 10b5-1 plan is generally treated as lower-signal than discretionary selling, implying limited immediate trading impact.

Market read

Traders may use the disclosure as a sentiment check, but it is unlikely to drive a fundamental repricing by itself.

What to watch

The article provides only the sale details; it does not include any concurrent buys, option exercises, or changes in other insiders’ activity that could contextualize the signal.

Relevance 3/10Novelty 5/10Timing: SEC Form 4 filed 2026-07-01 (sale executed 2026-06-30)

Background

This is an SEC Form 4 insider transaction disclosure for Contineum Therapeutics, Inc. (CTNM).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CTNMNeutralMedium confidence

Context

Contineum Therapeutics CEO and President Stengone Carmine N. sold 10,000 shares on 2026-06-30 at $16.0080 via a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No sector-level implications; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of perceived valuation risk or liquidity needs, so traders may still watch for follow-on selling.

Key entities

issuer
Contineum Therapeutics, Inc.
Subject of the Form 4 insider transaction; CEO/President sold shares under a 10b5-1 plan.
insider
Stengone Carmine N.
CEO and President who executed the reported sale.

Read at source ← All news

SEP 25

$CTNMMedAI 8/10

J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?

Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.

insidermonkey.com4 min

SEP 24

$CTNMMed

Goldman Sachs initiates coverage on Contineum Therapeutics stock

Goldman Sachs initiated coverage on Contineum Therapeutics (NASDAQ:CTNM) with an Early-Stage Biotech rating. The stock trades at $12.51, down 5.3% in a week. The company is developing oral therapies for inflammatory and fibrotic conditions. Its lead candidate, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. Despite a recent trial failure, Stifel maintains a Buy rating with a $28 price target.

investing.com2 min

SEP 15

$CTNMMedAI 8/10

Contineum Therapeutics Tumbles After Depression Drug Misses Primary Goal in Phase 2 — BigGo Finance

Contineum Therapeutics (CTNM) shares fell in after-hours trading after its depression drug candidate, licensed to Johnson & Johnson (JNJ), missed the primary efficacy endpoint in a Phase 2 trial. This is the second Phase 2 failure for the same molecule in less than a year. The company's focus shifts to its lung-disease program, PIPE-791. JNJ is evaluating the trial data, but no decision on further development has been made. Contineum shares declined 3.5% to $14.30 in after-hours trading, while J

finance.biggo.com2 min

SEP 15

$CTNMMed

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Contineum Therapeutics (CTNM) shares fell 9.58% after its Phase 2 MOONLIGHT-1 trial for depression drug JNJ-5120/PIPE-307, developed with Johnson & Johnson (JNJ), missed its primary efficacy endpoint. JNJ is reviewing data to determine next steps. CTNM's stock is near key support at $13.60 and resistance at $15.34.

aol.com2 min

SEP 14

$CTNMHighAI 8/10

CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?

Contineum Therapeutics (CTNM) shares fell 10% after-hours after J&J's (JNJ) mid-stage trial of PIPE-307, licensed from CTNM, failed to meet its primary goal in treating major depressive disorder. This is the second mid-stage setback for the molecule in under a year. JNJ is reviewing exploratory measures and has not decided on further development. CTNM has $236.6 million in cash, expected to last through mid-2029.

newsable.asianetnews.com2 min